Alnylam Pharmaceuticals | ALNY - 销售和管理费用

金融业

USD 156.66

USD 7.99B

现金及等价物

USD 1.75B

USD 361.75M

USD 5.11B

USD 2.06B

USD 2.48B

USD 179.66M

USD 360.27M

2.23K

EPS每股收益

USD 16.26

股本和储备

USD 3.6B

USD 930.2M

债务利息支出

USD -84.37M

USD 28.14M

USD 2.11B

USD 21.57B

USD 2.17B

USD 1.11B

USD 179.66M

普通股股本

USD 133.88M

13.17

USD 295.81M

USD 1.46B

销售和管理费用

USD 342M

USD 105.91M

贸易债权人

USD 135.4M

应收帐款人

USD 1.08B

	销售和管理费用	更改		日
Acadia Pharmaceuticals	USD 146.88M		1.69M	2026-09
Agios Pharmaceuticals	USD 51.55M		13.09M	2026-06
Alnylam Pharmaceuticals	USD 342M		5.92M	2026-09
Amgen	USD 1.68B		40M	2026-09
Arrowhead Research	USD 46.63M		4.88M	2026-06
BioCryst Pharmaceuticals	USD 63.98M		31.8M	2026-06
BioMarin Pharmaceutical	USD 333.64M		61.91M	2026-09
Incyte	USD 364.27M		12.54M	2026-09
Ionis Pharmaceuticals	USD 130.07M		20.92M	2026-06
Moderna	USD 216M		43M	2026-06
Neurocrine Biosciences	USD 366.3M		16.8M	2026-09
Novartis	USD 3.08B		58M	2026-09
PTC Therapeutics	USD 80.63M		6.74M	2026-06
Regeneron Pharmaceuticals	USD 662.1M		14.4M	2026-06
Sangamo BioSciences	USD 9.64M		1.83M	2024-06
Sanofi	EUR 2.63B		140M	2026-06
Sarepta Therapeutics	USD 107.6M		53.57M	2026-06
Takeda	JPY 271.71B		14.8B	2026-09
Tectonic Therapeutic	USD 6.17M		260K	2026-06
Ultragenyx Pharmaceutical	USD 97M		9M	2026-09
Vertex Pharmaceuticals	USD 556.3M		25.9M	2026-09
Xencor	USD 71.93M		5.61M	2026-09